Business Context and Reporting Period
This Form 8-K is a current report filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) on March 10, 2025. The filing addresses a corporate event regarding a registered offering of common stock under an existing At-the-Market (ATM) agreement.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, or debt levels. The only financial figure disclosed relates to the capital raising activity:
- Offering Capacity: Up to $417,000 of common stock shares.
- Stock Details: Common Stock, par value $0.0001 per share, trading under symbol SLRX on The Nasdaq Capital Market.
Material Changes
The material change reported is the filing of a Prospectus Supplement to the Company's effective Form S-3 Registration Statement (File No. 333-266589), originally declared effective on August 16, 2022. This action updates the registration for the sale of shares pursuant to the At-the-Market Offering Agreement with Ladenburg Thalmann & Co. Inc., dated February 5, 2021.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It does not disclose specific risks or contingencies beyond the standard legal opinion regarding the validity of the shares being registered. The document primarily serves to satisfy disclosure requirements for the prospectus supplement.
Investor Verification Checklist
- Verify the current market price of SLRX to assess the potential dilution impact of the $417,000 offering.
- Review the full Prospectus Supplement (referenced in Item 8.01) for specific terms of the share sale.
- Confirm the Company's current cash position and burn rate in the most recent 10-Q or 10-K, as this filing does not provide liquidity data.
- Note the discrepancy between the requested company name (Decoy Therapeutics) and the filing registrant (Salarius Pharmaceuticals).